Bio-Imaging Technologies to Present at the BMO Capital Markets 8th Annual Focus on Healthcare Conference August 6, 2008 in New York
Posted on: Thursday, 31 July 2008, 09:01 CDT
Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced that it is scheduled to present at the BMO Capital Markets 8th Annual Focus on Healthcare Conference on Wednesday August 6, 2008 at 9:30 a.m. EDT. A webcast of the presentation will be accessible at http://www.bmocm.com/conferences/2008healthcare/webcast/default.aspx.
The conference will be held August 5-6, 2008, at the Millennium Broadway Hotel in New York City.
Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its Core Labs in Newtown, PA, and Leiden, The Netherlands, along with business offices in the United States, The Netherlands, Germany and France. Phoenix Data Systems, Inc., a subsidiary of Bio-Imaging Technologies, is a leading global clinical data services provider of electronic data capture (EDC) services and a comprehensive array of broadly interoperable eClinical data solutions to the pharmaceutical and biotechnology industries. Phoenix Data Systems delivers full service EDC, a unique combination of electronic data capture, interactive voice response, reporting, and data management solutions. Through its CapMed Personal Health Management Suite, Bio-Imaging provides its Personal HealthKey(TM) technology, the Personal Health Record (PHR) software, and CapMed Patient Portal allowing patients to better monitor and manage their health care information. Additional information about Bio-Imaging is available at www.bioimaging.com.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.
Source: Business Wire
Related Articles
- Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
- Bio/Data Corporation Launches vW Select(TM) - The World's First and Only Complete Ristocetin CoFactor Assay
- IBM Healthcare Customers Implement Advanced Data Storage and Management Technologies
- Cytokinetics Announces Clinical Trial Data With Ispinesib and Non-Clinical Data With SB-743921 at the EORTC-NCI-AACR Symposium
- Bio/Data Targets Sticky Platelet Testing
- Bio/Data Corporation Expands Marketing Department
- Bio/Data Corporation Releases New Control Plasma for vW Testing
- Bio/Data Corporation Adds Extra Features to 8-Channel Platelet Aggregation Profiler(R); Instrument to Be Showcased at Hematology Confab
- Accentia Biopharmaceuticals Announces That Follow-Up Data From the Phase II Clinical Trial of BiovaxID(TM) Will Be Presented at the Annual Meeting of the American Society for Hematology
- LighthouseMD Announces New CareTracker 5.8 Practice Management and Clinical System Release
User Comments (0)

RSS Feeds